- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Ryan McDonald | Authors
Pembrolizumab Plus Concurrent Chemoradiation Continues to Induce Durable Responses in Previously Untreated Stage III NSCLC
June 07, 2022
Patients with previously untreated, locally advanced stage 3 non–small cell lung cancer continue to derive a benefit from pembrolizumab with concurrent chemoradiation followed by additional pembrolizumab after more than 2 years of follow-up.
First-line Ribociclib-AI Combo Associated with Better Symptom-Related QOL Vs Abemaciclib-AI in HR+/HER2− Advanced Breast Cancer
June 06, 2022
Results of a matching-adjusted indirect comparison study showed that patients with HR-positive/HER2–negative advanced breast cancer treated with ribociclib and an aromatase inhibitor were more likely to have better symptom-related quality of life than patients who received abemaciclib and an aromatase inhibitor.
Preliminary Results Show Second-line Lurbinectedin Plus Pembrolizumab Safe, Effective in Relapsed SCLC
June 06, 2022
Preliminary findings of data from the phase 1/2 LUPER study demonstrate that treatment with lurbinectedin combined with pembrolizumab elicits promising efficacy in patients with metastatic small-cell lung cancer that has failed to respond to chemotherapy.
Long-Term Follow-Up Continues to Show Acalabrutinib-Based Regimens Superior to Obinutuzumab Plus Chemo in Treatment-Naïve CLL
June 04, 2022
At approximately 5 years of follow-up, findings from the phase 3 ELEVATE-TN study show that treatment outcomes are more favorable with acalabrutinib with or without obinutuzumab compared with obinutuzumab and chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Despite Increased Use of Telemedicine for Cancer Care During COVID-19, Disparities Persist
May 26, 2022
The findings of this retrospective study of more than 25,000 patients with cancer newly diagnosed during the COVID-19 pandemic highlight a need to reduce the inequities in telemedicine use for cancer care, according to the study’s lead author.
Pembrolizumab Combo Yields Durable Response in Treatment-Refractory mCRC
January 22, 2022
Pembrolizumab, binimetinib , and bevacizumab led to deep and durable responses for patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer.
Venetoclax Combination Regimen Yields Robust Reponses in t(11;14) Relapsed/Refractory Multiple Myeloma
December 14, 2021
Patients with relapsed/refractory t(11;14) multiple myeloma appeared to benefit from treatment with venetoclax at a dose of 400 mg or 800 mg plus daratumumab/dexamethasone.
MRD-Guided Ibrutinib Plus Venetoclax Feasible Treatment Option for Relapsed/Refractory CLL
December 11, 2021
The combination of MRD-guided ibrutinib and venetoclax demonstrated feasibility for treating patients with relapsed/refractory chronic lymphocytic leukemia.
Breast Cancer-Related Lymphedema Occurs More Often in Black Women vs White Women
December 07, 2021
Black women with breast cancer had a 3.5-fold higher rate of lymphedema over 24 months compared with White women.
Clinical Efficacy of Nivolumab Plus Rucaparib Revealed in mCRPC Subgroup
September 19, 2021
Certain patients with metastatic castration-resistant prostate cancer may have favorable outcomes after receiving nivolumab plus rucaparib.